| Title： | Chinese Clinical Expert Consensus on Immunotherapy for Hepatocellular Carcinoma（2021） |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | Doctor |
| Evidence classification method： | IA evidence derived from Meta-analysis results of multiple randomized controlled studies IB evidence derived from at least one well-designed randomized controlled study IIA evidence derived from at least one well-designed prospective non-randomized controlled study IIB evidence derived from at least one well-designed other type of intervention clinical study III evidence derived from a well-designed non-intervention study, such as descriptive studies, Correlation Studies and other IV evidence from Expert Committee reports or authoritative clinical experience of experts reported |
| Development unit： | Chinese Association of Liver Cancer |
| Registration time: | 2022-03-06 |
| Registration number： | IPGRP-2022CN108 |
| Purpose of the guideline: | To standard the immunotherapy for hepatocellular carcinoma(HCC) |
Latest registration
